Publications

Dr Afsar Mian

Papers 

  1. Ali S, Khan FA, Mian AA, and Afzal MS (2014). Seroprevalence of cytomegalovirus, herpes simplex virus and rubella virus among pregnant women in KPK province of Pakistan. J Infect Dev Ctries, 8(3), 389-390. doi:10.3855/jidc.3854. Link

  2. Beissert T, Hundertmark A, Kaburova V, Travaglini L, Mian AA, Nervi C, and Ruthardt M (2008). Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR/ABL. Int J Cancer, 122(12), 2744-2752. doi:10.1002/ijc.23467. Link

  3. Haberbosch I, Rafiei A, Oancea C, Ottmann GO, Ruthardt M, and Mian AA (2016). BCR: a new target in resistance mediated by BCR/ABL-315I? Genes Cancer, 7(1-2), 36-46. doi:10.18632/genesandcancer.93. Link

  4. Khateb M, Ruimi N, Khamisie H, Najajreh Y, Mian AA, Metodieva A, . . . Mahajna J (2012). Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism. BMC Cancer, 12, 563. doi:10.1186/1471-2407-12-563. Link

  5. Legut M, Dolton G, Mian AA, Ottmann OG and Sewell AK (2018). CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells. Blood, 131(3), 311-322. doi:10.1182/blood-2017-05-787598. Link

  6. Mian AA, Haberbosch I, Ottmann GO and Ruthardt M (2104). Transphosphorylation of Endogenous BCR Mediates the Effect of T315I on the Transformation Potential of BCR/ABL. Bloodjournal, 124(21), 4523. Link

  7. Mian AA, Metodieva A, Badura S, Khateb M, Ruimi N, Najajreh Y, . . . Ruthardt M (2012). Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I. BMC Cancer, 12, 411. doi:10.1186/1471-2407-12-411. Link

  8. Mian AA, Metodieva A, Najajreh Y, Ottmann OG, Mahajna J and Ruthardt M (2012). p185(BCR/ABL) has a lower sensitivity than p210(BCR/ABL) to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia. Haematologica, 97(2), 251-257. doi:10.3324/haematol.2011.047191. Link

  9. Mian AA, Metodieva A, Najajreh Y, Serve H, Ottmann OG, Mahajna J and Ruthardt M (2010). The Degree of Response of Philadelphia Chromosome Positive Acute Lymphatic Leukemia to Allosteric Inhibition by GNF-2 Depends on the Presence of Either p185-BCR/ABL or p210-BCR/ABL. Bloodjournal, 116(21), 598. Link

  10. Mian AA, Oancea C, Zhao Z, Ottmann OG and Ruthardt M (2009). Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR/ABL. Leukemia, 23(12), 2242-2247. doi:10.1038/leu.2009.194. Link

  11. Mian AA, Rafiei A, Haberbosch I, Zeifman A, Titov I, Stroylov V, . . . Ruthardt M (2015). PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation. Leukemia, 29(5), 1104-1114. doi:10.1038/leu.2014.326. Link

  12. Mian AA, Rafiei A, Metodieva A, Haberbosch I, Zeifman A, Titov I, . . . Ruthardt M (2013). PF-114, a Novel Selective Pan BCR/ABL Inhibitor Targets The T315I and Suppress Models Of Advanced Ph+ ALL. Bloodjournal, 122(21), 3907.  Link

  13. Mian AA, Schull M, Oancea C, Najajreh Y, Mahajna J, Goldblum A, . . . Ruthardt M (2011). Targeting the Oligomerization of BCR/ABL by Membrane Permeable Competitive Peptides Inhibits the Proliferation of Philadelphia Chromosome Positive Leukemic Cells. The Open Hematology Journal, 5, 21-27. doi:10.2174/1874276901105010021. Link

  14. Mian AA, Schull M, Zhao Z, Oancea C, Hundertmark A, Beissert T, . . . Ruthardt M (2009). The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR/ABL. Leukemia, 23(9), 1614-1621. doi:10.1038/leu.2009.69. Link

  15. Oancea C, Ruster B, Brill B, Roos J, Heinssmann M, Bug G, Mian AA . . . Ruthardt M (2014). STAT activation status differentiates leukemogenic from non-leukemogenic stem cells in AML and is suppressed by arsenic in t(6;9)-positive AML. Genes Cancer, 5(11-12), 378-392. doi:10.18632/genesandcancer.39. Link

  16. Rafiei A, Mian AA, Doring C, Metodieva A, Oancea C, Thalheimer FB, . . . Ruthardt M (2015). The functional interplay between the t(9;22)-associated fusion proteins BCR/ABL and ABL/BCR in Philadelphia chromosome-positive acute lymphatic leukemia. PLoS Genet, 11(4), e1005144. doi:10.1371/journal.pgen.1005144. Link